TS
AKRO

Thomas Steyer’s Akero Therapeutics AKRO Stock Holding History

Thomas Steyer’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,000
Closed -$213K – 146
2025
Q2 		$213K Buy
+4,000
New +$182K ﹤0.01% 118
2023
Q4 		– Sell
-4,000
Closed -$202K – 159
2023
Q3 		$202K Buy
+4,000
New +$186K ﹤0.01% 128
2019
Q3 		– Sell
-150,000
Closed -$2.87M – 101
2019
Q2 		$2.87M Buy
+150,000
New +$2.84M 0.02% 97

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's AKRO Position: Q3 2025 in Review

Thomas Steyer sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 4,000 shares — an estimated $213K sold.

Thomas Steyer first reported a position in AKRO in Q2 2019 and held it in 3 quarters. The position peaked at $2.87M in Q2 2019. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Thomas Steyer reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Thomas Steyer sold 4,000 Akero Therapeutics shares in Q3 2025, an estimated $213K.
  • Thomas Steyer first reported a position in Akero Therapeutics in Q2 2019 and held it in 3 quarters.
  • Thomas Steyer's Akero Therapeutics position peaked at $2.87M in Q2 2019.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Farallon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.